Dermatitis News

The prevalence of current eczema increased by 0.98% per decade among adolescents and 1.21% per decade among children over a span of 27 years, according to a study published in Clinical & Experimental Allergy.

Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment of atopic dermatitis in adolescents and adults, according to a phase 3 study.

Genetic variants related to GERD heightened risks for both asthma and atopic dermatitis by 21%, according to study results published in American Journal of Respiratory and Critical Care Medicine.

Children with atopic dermatitis who received dupilumab experienced improvements in disease severity and decreases in severity-associated serum biomarkers, according to a study published in Pediatric Allergy and Immunology.

The European Medicines Agency has recommended extending Dupixent approval to treat severe atopic dermatitis in children aged 6 months to 5 years in the European Union, Regeneron Pharmaceuticals and Sanofi announced in a press release.

Infants living in urban areas had lower transepidermal water loss values than infants in rural areas, according to a letter published in Pediatric Allergy and Asthma.

Previously administered orally, brepocitinib proved to be effective and well tolerated as a topical formation in patients with mild to moderate atopic dermatitis, according to a phase 2b study.

Tralokinumab, a high-affinity monoclonal antibody that specifically neutralizes interleukin-13, improved microbial diversity and reduced Staphylococcus aureus among patients with moderate to severe atopic dermatitis, according to a study.

The FDA’s approval of Rinvoq, a selective Janus kinase (JAK) inhibitor, was Healio’s most read dermatitis story in 2022, with multiple articles about Cibinqo and roflumilast following close behind.

Arcutis Biotherapeutics announced positive topline results from its phase 3 trial of roflumilast cream in adults and children aged 6 years and older with mild to moderate atopic dermatitis, according to a company press release.